Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    - Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-06T16:04:32.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Update to bibliographic metadata: upgrade the citation to v3.1.0 and removal of an explicit erratum reference, indicating a versioned citation change with no new content added.
    Difference
    0.3%
    Check dated 2025-09-29T10:00:04.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Updated to revision v3.0.2 and removed the v3.0.1 tag along with the 'Back to Top' link. This is a minor maintenance update with no substantive changes to core content, pricing, or time slot information.
    Difference
    0.2%
    Check dated 2025-09-15T00:58:03.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T21:05:46.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to include specific details about Hodgkin lymphoma treatment efficacy, including a new facility name and location, while removing several previous location-related terms and some medical terminology.
    Difference
    3%
    Check dated 2025-08-30T15:32:57.000Z thumbnail image
  8. Check
    55 days ago
    Change Detected
    Summary
    The web page has removed a significant publication reference regarding the five-year follow-up of pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
    Difference
    0.3%
    Check dated 2025-08-23T14:11:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.